Rosuvastatin should not be given to patients with acute liver disease or unexplained persistent raised serum-aminotransferase concentrations. It should be avoided during pregnancy since there is a possibility that it could interfere with fetal sterol synthesis; there have been a few reports of congenital abnormalities associate with HMG-CoA reductase inhibitors. It should be discontinued if marked increases in serum-aminotransferase or creatinine-phosphokinase concentrations occur.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
